Madrigal Pharmaceuticals (MDGL) reported $958M in revenue for fiscal 2025, +432.1% year on year. That ranks #1801 by revenue among 2853 SEC filers and #163 in Healthcare. It posted a net loss of −$288M for the same year. Revenue has grown 96.5% a year on average since 2012 ($147,000 then). The fiscal 2025 balance sheet shows $1.3B in total assets, $199M in cash and $340M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $958M | +432.1% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$300M | +$198M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$288M | +$178M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$190M | +$266M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $467,000 | −68.1% | FY20252025-12-31 |
| Total assetsAssets | $1.3B | +20.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $603M | −20.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $199M | +98.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $340M | +189.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $311M | −$94.4M | Open → |
| Q2 20262026-06-30 | $364M | −$57.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Madrigal Pharmaceuticals, Inc.
- Ticker
- MDGL
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001157601
Filings
- 10-QJul 30, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Legend BiotechLEGN | $1.0B | −$297M |
| Tandem Diabetes CareTNDM | $1.0B | −$205M |
| Guardant HealthGH | $982M | −$416M |
| Madrigal PharmaceuticalsMDGL | $958M | −$288M |
| Pennant GroupPNTG | $948M | $29.6M |
| Ionis PharmaceuticalsIONS | $944M | −$381M |
| Usana Health SciencesUSNA | $925M | $10.8M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Madrigal Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/madrigal-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Madrigal Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/madrigal-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-madrigal-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Madrigal Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/madrigal-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-009514 · February 19, 2026
{{cite web |title=Madrigal Pharmaceuticals — Key figures — 10-K (0001628280-26-009514) |url=https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.